Jessica E Haberer1. 1. aCenter for Global Health, Massachusetts General Hospital bDepartment of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Abstract
PURPOSE OF REVIEW: The review describes the current understanding of adherence to oral preexposure prophylaxis (PrEP), methods for adherence measurement, approaches to supporting PrEP adherence, and guidance for defining PrEP adherence goals within the larger context of HIV prevention. RECENT FINDINGS: PrEP adherence has generally been higher in recent trials, open-label extensions, and demonstration projects compared with the initial clinical trials; potential explanations include known PrEP efficacy and different motivations to take PrEP. Recent studies have explored adherence monitoring through electronic pill containers, short message service (SMS), and drug concentrations in hair and dried blood spots. The few PrEP adherence interventions developed to date include combinations of enhanced counseling, feedback of objective adherence measurement, and SMS. Conceptualization of PrEP adherence is evolving. The goal is not 100% adherence indefinitely, as it was in clinical trials. PrEP adherence should be defined with respect to HIV exposure, which varies over time by sexual behavior and use of other prevention strategies. SUMMARY: PrEP adherence beyond clinical trials has generally been high enough to achieve reliable HIV prevention. Future efforts to measure and support PrEP adherence should focus on the context of risk for HIV acquisition, accounting for dynamic behaviors and choices among HIV prevention options.
PURPOSE OF REVIEW: The review describes the current understanding of adherence to oral preexposure prophylaxis (PrEP), methods for adherence measurement, approaches to supporting PrEP adherence, and guidance for defining PrEP adherence goals within the larger context of HIV prevention. RECENT FINDINGS: PrEP adherence has generally been higher in recent trials, open-label extensions, and demonstration projects compared with the initial clinical trials; potential explanations include known PrEP efficacy and different motivations to take PrEP. Recent studies have explored adherence monitoring through electronic pill containers, short message service (SMS), and drug concentrations in hair and dried blood spots. The few PrEP adherence interventions developed to date include combinations of enhanced counseling, feedback of objective adherence measurement, and SMS. Conceptualization of PrEP adherence is evolving. The goal is not 100% adherence indefinitely, as it was in clinical trials. PrEP adherence should be defined with respect to HIV exposure, which varies over time by sexual behavior and use of other prevention strategies. SUMMARY: PrEP adherence beyond clinical trials has generally been high enough to achieve reliable HIV prevention. Future efforts to measure and support PrEP adherence should focus on the context of risk for HIV acquisition, accounting for dynamic behaviors and choices among HIV prevention options.
Authors: Robert M Grant; Peter L Anderson; Vanessa McMahan; Albert Liu; K Rivet Amico; Megha Mehrotra; Sybil Hosek; Carlos Mosquera; Martin Casapia; Orlando Montoya; Susan Buchbinder; Valdilea G Veloso; Kenneth Mayer; Suwat Chariyalertsak; Linda-Gail Bekker; Esper G Kallas; Mauro Schechter; Juan Guanira; Lane Bushman; David N Burns; James F Rooney; David V Glidden Journal: Lancet Infect Dis Date: 2014-07-22 Impact factor: 25.071
Authors: Monica Gandhi; David V Glidden; Albert Liu; Peter L Anderson; Howard Horng; Patricia Defechereux; Juan V Guanira; Beatriz Grinsztejn; Suwat Chariyalertsak; Linda-Gail Bekker; Robert M Grant Journal: J Infect Dis Date: 2015-04-20 Impact factor: 5.226
Authors: Michael C Thigpen; Poloko M Kebaabetswe; Lynn A Paxton; Dawn K Smith; Charles E Rose; Tebogo M Segolodi; Faith L Henderson; Sonal R Pathak; Fatma A Soud; Kata L Chillag; Rodreck Mutanhaurwa; Lovemore Ian Chirwa; Michael Kasonde; Daniel Abebe; Evans Buliva; Roman J Gvetadze; Sandra Johnson; Thom Sukalac; Vasavi T Thomas; Clyde Hart; Jeffrey A Johnson; C Kevin Malotte; Craig W Hendrix; John T Brooks Journal: N Engl J Med Date: 2012-07-11 Impact factor: 91.245
Authors: Sybil G Hosek; George Siberry; Margo Bell; Michelle Lally; Bill Kapogiannis; Keith Green; M Isabel Fernandez; Brandy Rutledge; Jaime Martinez; Robert Garofalo; Craig M Wilson Journal: J Acquir Immune Defic Syndr Date: 2013-04-01 Impact factor: 3.731
Authors: Peter Mwangi Mugo; Eduard J Sanders; Gaudensia Mutua; Elisabeth van der Elst; Omu Anzala; Burc Barin; David R Bangsberg; Frances H Priddy; Jessica E Haberer Journal: AIDS Behav Date: 2015-05
Authors: Sanjiv M Baxi; Albert Liu; Peter Bacchetti; Gaudensia Mutua; Eduard J Sanders; Freddie M Kibengo; Jessica E Haberer; James Rooney; Craig W Hendrix; Peter L Anderson; Yong Huang; Frances Priddy; Monica Gandhi Journal: J Acquir Immune Defic Syndr Date: 2015-01-01 Impact factor: 3.731
Authors: Peng Xiao; Sanjeev Gumber; Mark A Marzinke; Abhijit A Date; Thuy Hoang; Justin Hanes; Laura M Ensign; Lin Wang; Lisa Rohan; Edward J Fuchs; Craig Hendrix; Francois Villinger Journal: Antimicrob Agents Chemother Date: 2017-12-21 Impact factor: 5.191
Authors: H C Koenig; K Mounzer; G W Daughtridge; C E Sloan; L Lalley-Chareczko; G S Moorthy; S C Conyngham; A F Zuppa; L J Montaner; P Tebas Journal: HIV Med Date: 2017-04-26 Impact factor: 3.180
Authors: Valentine Wanga; Jared M Baeten; Elizabeth A Bukusi; Nelly R Mugo; Stephen Asiimwe; Kenneth Ngure; Andrew Mujugira; Timothy Muwonge; Josephine B Odoyo; Jessica E Haberer; Connie Celum; Renee Heffron Journal: AIDS Behav Date: 2020-07
Authors: Philip A Chan; William C Goedel; Amy S Nunn; Genoviva Sowemimo-Coker; Omar Galárraga; Mattia Prosperi; Rupa Patel; Leandro Mena; Madeline C Montgomery; Brandon D L Marshall Journal: AIDS Patient Care STDS Date: 2019-10 Impact factor: 5.078
Authors: Hannah N Gilbert; Monique A Wyatt; Emily E Pisarski; Timothy R Muwonge; Renee Heffron; Elly T Katabira; Connie L Celum; Jared M Baeten; Jessica E Haberer; Norma C Ware Journal: J Acquir Immune Defic Syndr Date: 2019-11-01 Impact factor: 3.731
Authors: Christian Grov; Anthony W P Flynn; Alexa B D'Angelo; Javier Lopez-Rios; David W Pantalone; Ian W Holloway; Jeffrey T Parsons Journal: Prev Sci Date: 2019-01
Authors: Sarah A Gutin; Gary W Harper; K Rivet Amico; Christina Bitsang; Neo Moshashane; Jane Harries; Doreen Ramogola-Masire; Chelsea Morroni Journal: Glob Public Health Date: 2020-03-16